SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sobol RE, Royston I, LeBien TW, et al. Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood. 1985; 65: 730735.
  • 2
    Foon KA, Billing RJ, Terasaki PI, Cline MJ. Immunologic classification of acute lymphoblastic leukemia. Implications for normal lymphoid differentiation. Blood. 1980; 56: 11201126.
  • 3
    Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia – current concepts and future perspectives. Rev Clin Exp Hematol. 2002; 6.2: 142160; discussion 200–202.
  • 4
    Seiter K. Acute lymphoblastic leukemia. Available at: www.emedicine.com/med/topic3146.htm Last updated August 3, 2006.
  • 5
    Hoelzer D, Gokbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol. 2000; 36: 4958.
  • 6
    Satake N. Acute lymphoblastic leukemia. Available at: www.emedicine.com/ped/topic2587.htm Last updated: July 11, 2006.
  • 7
    Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem. 2000; 275: 1858118585.
  • 8
    Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia — results of the prospective multicenter LALA-94 trial. Blood. 2002; 100: 23572366.
  • 9
    Paul MK, Mukhopadhyay AK. Tyrosine kinase – role and significance in cancer. Int J Med Sci. 2004; 1: 101115.
  • 10
    Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukemia. Acta Haematol. 2002; 108: 180202.
  • 11
    Mughal TI, Goldman JM. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? Front Biosci. 2006; 11: 198208.
  • 12
    Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2005: 118122.
  • 13
    Onciu M, Bueso-Ramos C, Medeiros J, Ball G, Smith T, Lai R. Acute lymphoblastic leukemia in elderly patients: The Philadelphia chromosome may not be a significant adverse prognostic factor. Am J Clin Pathol. 2002; 117: 716720.
  • 14
    Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001; 97: 15721577.
  • 15
    Piccaluga PP, Martinelli G, Rondoni M, Visani G, Baccarani M. Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. Expert Opin Biol Ther. 2006; 6: 10111022.
  • 16
    Bloomfield CD, Secker-Walker LM, Goldman AI, et al. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1989; 40: 171185.
  • 17
    Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991; 5: 196199.
  • 18
    Gotz G, Weh HJ, Walter TA, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol. 1992; 64: 97100.
  • 19
    Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL1 fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B study. Blood. 1992; 80: 29832990.
  • 20
    Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 1995; 85: 20252037.
  • 21
    Group Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Francais de Cytogenetique Hematologique. Blood. 1996; 87: 31353142. Erratum in: Blood. 1996; 88: 2818.
  • 22
    Chim CS, Kwong YL, Chu YC, Chan CH, Chan YT, Liang R. Improved treatment outcome in adult acute lymphoblastic leukemia using the intensive German protocol, a preliminary report. Hematol Oncol. 1997; 15: 1926.
  • 23
    Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA.MRC Adult Leukaemia Working Party. Br J Haematol. 1997; 96: 601610.
  • 24
    Thomas X, Thiebaut A, Olteanu N, et al. Philadelphia chromosome-positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther. 1998; 40: 119128.
  • 25
    Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999; 93: 39833993.
  • 26
    Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000; 36: 263273.
  • 27
    Ko BS, Tang JL, Tsai W, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in Taiwan. Ann Hematol. 2001; 80: 510515.
  • 28
    Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol. 2001; 67: 7383.
  • 29
    Thomas X, Danaila C, Le QH, et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21 year period. Leukemia. 2001; 15: 18111822.
  • 30
    Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002; 99: 863871.
  • 31
    Manley PW, Cowan-Jacob E, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer. 2002; 38( suppl 5): S19S27.
  • 32
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 10381042. Erratum in: N Engl J Med. 2001; 345: 232.
  • 33
    Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemia. Blood. 2002; 100: 19651971.
  • 34
    Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib. Blood. 2004; 103: 14951498.
  • 35
    Piccaluga PP, Malagola M, Amabile M, et al. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. Haematologica. 2004; 89: 12691271.
  • 36
    Wassmann B, Pfeifer H, Scheuring U, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia. 2002; 16: 23582365.
  • 37
    Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103: 43964407.
  • 38
    Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006; 24: 460466.
  • 39
    Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive lymphoblastic leukemia (Ph+ ALL). Blood. 2006; 108: 14691477.
  • 40
    Vignetti M, Fazi P, Meloni G, et al. Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients: results of the GIMEMA prospective study LAL0201 [abstract]. Blood. 2004; 104. Abstract 2739.
  • 41
    Ottmann OG, Wassmann B, Gokbuget N, et al. A randomized phase II study comparing imatinib with chemotherapy as induction therapy in elderly patients with newly diagnosed Philadelphia-positive acute lymphoid leukemia (Ph+ ALL) [abstract]. Hematol J. 2004; 5: S112.
  • 42
    de Labarthe A, Rousselot P, Huget-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia – results of the GRAAPH-2003 study. Blood. 2007; 109: 14081413.
  • 43
    Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2005; 105: 34493457.
  • 44
    Daub H, Specht K, Ullurich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov. 2004; 3: 10011010.
  • 45
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876880.
  • 46
    Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2: 117125.
  • 47
    Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kurivan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 2000; 289: 19381942.
  • 48
    Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005: 183187.
  • 49
    Pfeifer H, Wassmann B, Pavlova A, et al. Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) developing resistance to imatinib [abstract]. Blood. 2005; 106: 46a. Abstract 147.
  • 50
    Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006; 108: 23322338.
  • 51
    Soverini S, Martinelli G, Colarossi S, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol. 2006; 20: 24: e5152.
  • 52
    Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin- 1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxyamide (BMS-354825), a dual SRC/abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47: 66586661.
  • 53
    Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825) a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006; 66: 473481.
  • 54
    Lee FY, Lombardo L, Camuso A, et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo [abstract]. Proc Amer Assoc Cancer Res. 2005; 46. Abstract 675.
  • 55
    O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS -354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005; 65: 45004505.
  • 56
    Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 25312541.
  • 57
    Baccarani M, Kantarjian HM, Apperley JF, et al. Efficacy of dasatinib (Sprycel) in patients with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 START-C Phase II Study. Presented at the 48th Annual Meeting of the American Society of Hematology, December 9–12, 2006, Orlando, Florida. (to be published).
  • 58
    Cortes J, Kim DW, Guilhot F, et al. Dasanitib (Sprycel) in Patients With Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That is Imatinib-Resistant or –Intolerant: Updated Results of the CA180-005 START-A Phase II Study. Presented at the 48th Annual Meeting of the American Society of Hematology, December 9–12, 2006, Orlando, Florida. (to be published).
  • 59
    Martinelli G, Hochhaus A, Coutre S, et al. Dasatinib (Sprycel) Efficacy and Safety in Patients (pts) With Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase who are Imatinib-resistant or –intolerant. Presented at the 48th Annual Meeting of the American Society of Hematology, December 9–12, 2006, Orlando, Florida. (to be published).
  • 60
    Dombret H, Ottmann OG, Rosti G, et al. Dasatinib (Sprycel) in Patients (pts) With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia who are Imatinib-Resistant or –Intolerant: Updated Results From the CA180-015 START-L Study. Presented at the 48th Annual Meeting of the American Society of Hematology, December 9–12, 2006, Orlando, Florida. Blood. 2006; 108: 286.
  • 61
    Shah N, Pasquini R, Rousselot P, et al. Dasatinib (Sprycel) vs Escalated Dose of Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: results of the CA180-017 START-R Randomized Study. Presented at the 48th Annual Meeting of the American Society of Hematology, December 9–12, 2006, Orlando, Florida. Blood. 2006;108: 167.
  • 62
    Coutre S, Martinelli G, Dombret H, et al. Dasatinib in patients with chronic myelogenous leukemia in lymphoid blast crisis or Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib resistant or intolerant: The CA180015 START-L study [abstract]. J Clin Oncol. 2006; 25( Suppl 18): 6528. Abstract 6528.
  • 63
    Ottmann O, Martinelli G, Dombret H, et al. Dasatinib in patients with chronic myelogenous leukemia in lymphoid blast crisis or Philadelphia chromosome-positive acute lymphoblastic leukemia that is imatinib-resistant or intolerant: The CA180015 START-L study [abstract]. Presented at the 11th Congress of the European Hematology Association, June 15–18, 2006, Amsterdam, Netherlands. Haematologica/The Hematol J. 2006;91(Suppl 1): 653. Abstract 0653.
  • 64
    Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl. Cancer Cell. 2005; 7: 129141.
  • 65
    Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 25422551.